the aid library

LIST OPTIONS

Filter

4354

Sort by:

Direction:

Download (269)

View PDF (1451)

IDF Diabetes Atlas 2021

International Diabetes Federation IDF (2022) C1

10th edition The IDF Diabetes Atlas 10th edition provides detailed information on the estimated and projected prevalence of diabetes, globally, by region, country and territory, for 2021, 2030 and 2045. It draws attention to the growing impact of diabetes across the world and highlights proven and ... more

Download (453)

View PDF (776)

Approaches for mobile and migrant populations in the context of malaria multi-drug resistance and malaria elimination in the Greater Mekong Subregion

World Health Organization ( WHO), Regional Oﬃce for South-East-Asia (2016) C_WHO

The emergence of multifrug-resistant malaria in the Greater Mekong Subregion (‎GMS)‎ has been identified as an emergency issue that may have catastrophic consequences on the future of malaria elimination in the GMS as well as globally. In recognition of the need for a cohesive regional response,... more

Download (149)

View PDF (330)

WHO technical guidance and specifications of medical devices for screening and treatment of precancerous lesions in the prevention of cervical cancer

World Health Organization WHO (2020) C_WHO

Globally, 311,000 women die of cervical cancer every year, 85 percent of them in resource limited regions of the world. To address this grave threat to women, the WHO made a call to action in 2018, resulting in accelerated plans to improve cervical cancer control under the elimination threshold w... more

Download (554)

View PDF (286)

Guideline for the pharmacological treatment of hypertension in adults
recommended

World Health Organization WHO (2021) C_WHO

The recommendations cover the level of blood pressure to start medication, what type of medicine or combination of medicines to use, the target blood pressure level, and how often to have follow-up checks on blood pressure. In addition, the guideline provides the basis for how physicians and other h... more

Download (73)

View PDF (431)

Guidelines for stopping mass drug administration and verifying elimination of human onchocerciasis: criteria and procedures

World Health Organization WHO (2016) C_WHO

Following the publication of Guidelines on certification of elimination of human onchocerciasis in 2001 by the World Health Organization (WHO), these are the first evidence-based guidelines developed by NTD Department according to the international standards. They provide a set of recommendations th... more

Download (181)

View PDF (152)

Pandemic influenza preparedness framework: partnership contribution high-level implementation plan III 2024-2030

World Health Organization WHO (2023) C_WHO

The Pandemic Influenza Pandemic (PIP) Framework's Partnership Contribution (PC) High-Level Implementation Plan III (HLIP III) outlines the strategy for strengthening global pandemic influenza preparedness from 2024 to 2030. HLIP III takes into consideration the lessons learned from the response to t... more

Download (151)

View PDF (143)

Multi-country outbreak of cholera, External situation report #4 - 6 July 2023

World Health Organisation (WHO) (2023) C_WHO

Since the last situation report on the multi-country outbreak of cholera was published on 1 June 2023 (covering data reported until 15 of May), no new country reported a cholera outbreak. In total, 24 countries have reported cases since the beginning of 2023. The WHO African Region remains the most ... more

Download (85)

View PDF (81)

Global monitoring report on financial protection in health 2021

World Health Organisation (WHO) (2021) C_WHO

The 2021 Global monitoring report on financial protection in health shows that before the COVID-19 pandemic, the world was off-track to reduce financial hardship due to health expenditures because trends in catastrophic health spending were going in the wrong direction and the number of people incur... more

Download (115)

View PDF (132)

Tracking Japan’s development assistance for health, 2012–2016

Nomura, S.; H. Sakamoto; M. K. Sugai et al. Globalization and Health (2020) CC

: Development assistance for health (DAH) is one of the most important means for Japan to promote diplomacy with developing countries and contribute to the international community. This study, for the first time, estimated the gross disbursement of Japan’s DAH from 2012 to 2016 and clarified its... more

Download (247)

View PDF (332)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (16)

View PDF (16)

Screening for cardiovascular disease risk and subsequent management in low and middle income countries: challenges and opportunities

Bovet, P.; Chiolero, A.; Paccaud, F. et al. Public Health Reviews (2015) CC

Background: Cardiovascular disease (CVD), mainly heart attack and stroke, is the leading cause of premature mortality in low and middle income countries (LMICs). Identifying and managing individuals at high risk of CVD is an important strategy to prevent and control CVD, in addition to multisector... more

Download (19)

View PDF (20)

Individual-level data in 680 102 adults, The state of diabetes treatment coverage in 55 low-income and middle-income countries: a cross-sectional study of nationally representative

Flood, D.; Seiglie, J.A.; Dunn, M.; et al. The Lancet healthy Longevity (2021) C2

Approximately 80% of the 463 million adults worldwide with diabetes live in low-income and middle-income countries (LMICs). A major obstacle to designing evidence-based policies to improve diabetes outcomes in LMICs is the scarce availability of nationally representative data on the current patterns... more

Download (26)

View PDF (24)

Experience of living with type 1 diabetes in a low-income country: a qualitative study from Liberia

Adler, A.J.; Trujillo, C.; Schwartz, L.; et al. BMJ Journals (2021) CC

While epidemiological data for type 1 diabetes (T1D) in low/middle-income countries, and particularly low-income countries (LICs) including Liberia is lacking, prevalence in LICs is thought to be increasing. T1D care in LICs is often impacted by challenges in diagnosis and management. These challeng... more

Download (28)

View PDF (24)

Burden of diabetes mellitus type 2 and its risk factors in Asia from 1990 to 2019: Updates from the 2019 Global Burden of Disease study

Khazaei, Z.; Momenabadi, V.; Badrizadeh, A.; et al. Research Square (2023) CC

The mounting burden of type 2 diabetes is a major concern in healthcare systems worldwide. The purpose of this study is to investigate the trend of type 2 diabetes from 1990 to 2019 in Asia.

Download (30)

View PDF (23)

Population and Individual Approach to the Prevention and Management of Diabetes and Obesity

Pan American Health Organization PAHO (2011) C_WHO

The Resolution Population and Individual Approaches to the Prevention and Management of Diabetes and Obesity was approved by the 48th Directing Council of the Pan American Health Organization, September 29- October 3, 2008, in response to the epidemic of obesity and diabetes currently affecting the ... more

Download (13)

View PDF (16)

Prevention of Cardiovascular Disease: Guidelines for assessment and management of cardiovascular risk

World Health Organization WHO (2007) C_WHO

Cardiovascular disease is a major cause of disability and premature death throughout the world, and contributes substantially to the escalating costs of health care. The underlying pathology is atherosclerosis, which develops over many years and is usually advanced by the time symptoms occur, genera... more

Download (19)

View PDF (26)

Population and Individual Approaches to the Prevention and Management of Diabetes and Obesity

Pan American Health Organization PAHO (2011) C_WHO

Obesity and diabetes are affecting the peoples of the Americas at high and increasing rates. National surveys demonstrate that obesity is increasing in prevalence among all age groups; 7% to 12% of children under 5 years old and one-fi fth of adolescents are obese, while rates of overweight and obe... more

Download (16)

View PDF (19)

Burden of fungal asthma in Africa: A systematic review and meta-analysis

Kwizera, R.; Musaazi, J.; Meya, D.B.; et al. PLOS ONE, which is part of the Public Library of Science (PLOS) (2019) CC2

Asthma is one of the neglected diseases in Africa with a high prevalence. Allergic fungal diseases have been reported to complicate asthma progression and treatment outcomes. However, data about fungal asthma and its associated complications are limited in Africa. We aimed to estimate the burden of ... more

Download (19)

View PDF (65)

WHO consolidated guidelines on tuberculosis Module 1: prevention - tuberculosis preventive treatment, second edition

World Health Organisation (WHO) (2024) C_WHO

About one fourth of the world’s population is estimated to have been infected with the tuberculosis (TB) bacilli, and about 5–10% of those infected develop TB disease in their lifetime. The risk for TB disease after infection depends on several factors, the most important being the person’s im... more

Guideline for the pharmacological treatment of hypertension in adults recommended

Guideline for the pharmacological treatment of hypertension in adults
recommended